Product Images Cialis

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Cialis NDC 43353-044 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 5mg - 43353 0044 04

Bottle Label 5mg - 43353 0044 04

This is a description of Tadalafil (Cialis). It is a medication available in a pack of 4 tablets with 5mg strength per tablet. The National Drug Code (NDC) for this drug is 43353004404. However, the text contains errors and non-English characters.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Chemical Structure - cialis uspi f001 structure v1

Chemical Structure - cialis uspi f001 structure v1

Figure - cialis uspi f001 v2

Figure - cialis uspi f001 v2

This is a chart that shows the concentration of tadalafil in plasma in micrograms per liter over time in hours, following the administration of different doses. The chart displays the results for a single 20mg tadalafil dose, a single 5mg tadalafil dose, and a once-daily 5mg tadalafil dose following 5 consecutive days of administration. The time points are labeled on the X-axis, and the concentration is labeled on the Y-axis.*

Figure - cialis uspi f002 v1

Figure - cialis uspi f002 v1

This is a chart that indicates the difference in blood pressure (in millimeters of mercury) between Tadalafil and a Placebo, specifically for Standing Systolic BP and Standing Diastolic BP. The chart also shows the values for Supine Systolic BP and Supine Diastolic BP at different time intervals. No other information is available.*

Figure - cialis uspi f003 v1

Figure - cialis uspi f003 v1

This appears to be a table or chart with numerical values and medication names. The medication names include "Tadalafil" and "doxazosin", which might indicate a comparison of drug effectiveness. There are also some numerical values, which could be measurements of some sort. Without more context, it is difficult to determine the exact purpose or meaning of this text. Therefore, a useful description cannot be provided.*

Figure - cialis uspi f004 v1

Figure - cialis uspi f004 v1

Figure 5 - cialis uspi f005 v1

Figure 5 - cialis uspi f005 v1

This is a graph showing the change from baseline in IPSS total score for a treatment group compared to a placebo group over the course of 12 weeks. There is a significant difference between the two groups indicated by the asterisk and the text "p<0.01". However, without more information about the study or treatment, it is difficult to draw further conclusions.*

Figure 6 - cialis uspi f006 v1

Figure 6 - cialis uspi f006 v1

This text is data from a medical study that reports changes in the International Prostate Symptom Score (IPSS) total score after treatment with either CIALIS 5mg or a placebo. The percentage change from the baseline is not specified in the text. The duration of treatment is shown on the x-axis of the graph shown, but the result is not available in the given text. The difference between the effects of CIALIS 5mg and the placebo is statistically significant (*p<0.01).*

Figure 7 - cialis uspi f007 v2

Figure 7 - cialis uspi f007 v2

Figure 8 - cialis uspi f008 v1

Figure 8 - cialis uspi f008 v1

The given text present the change from baseline in IPSS total score variable. There are two values mentioned, one for a medicine called CIAUS 5mg and the other for a placebo. The p-value for the difference between these two values is less than 0.01. The duration of treatment in both cases is 12 weeks.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.